Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06960395 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor Malignancies
EGFR Positive Solid Tumors
EGFR

Interventions

DRUG: VIR-5525
DRUG: Pembrolizumab

Sponsor

Vir Biotechnology, Inc.